SCHEMBL4305205

SCHEMBL4305205

CN1CCN(c2cccc(C(=O)N3CCC(c4ccc(F)cc4F)CC3)n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B14 Q9BPX1 1/20 0.51
FAAH O00519 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
USP2 O75604 1/20 0.43
MAPK1 P28482 1/20 0.43
CNR2 P34972 1/20 0.43
SCD5 Q86SK9 3/20 0.42
HTR1F P30939 2/20 0.42
CHRM5 P08912 1/20 0.42
DRD5 P21918 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1E P28566 1/20 0.42
HTR7 P34969 1/20 0.42
OPRK1 P41145 1/20 0.42
TMEM97 Q5BJF2 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
UBE2M P61081 1/20 0.41
DCUN1D1 Q96GG9 1/20 0.41
APLNR P35414 2/20 0.40
HRH4 Q9H3N8 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3466796 0.93 HSD17B14 (0.53) HSD17B14FAAHSMN1; SMN2USP2MAPK1
SCHEMBL3470360 0.91 HSD17B14 (0.48) HSD17B14FAAHSMN1; SMN2USP2MAPK1
SCHEMBL3469936 0.90 HSD17B14 (0.47) HSD17B14FAAHSMN1; SMN2USP2MAPK1
SCHEMBL3467150 0.90 HSD17B14 (0.50) HSD17B14SMN1; SMN2USP2MAPK1PRKCQ
SCHEMBL3466779 0.87 HSD17B14 (0.49) HSD17B14FAAHSMN1; SMN2USP2MAPK1
SCHEMBL4304173 0.86 HSD17B14 (0.47) HSD17B14SMN1; SMN2USP2MAPK1HRH4
SCHEMBL3467772 0.86 HSD17B14 (0.48) HSD17B14SMN1; SMN2USP2MAPK1CNR2
SCHEMBL3469979 0.85 USP2 (0.52) HSD17B14FAAHSMN1; SMN2USP2MAPK1
SCHEMBL4293433 0.84 HSD17B14 (0.48) HSD17B14
SCHEMBL3466177 0.82 HSD17B14 (0.49) HSD17B14FAAHSMN1; SMN2USP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US claimed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders HTR6, HTR5A, TPH1 HSD17B14 2214/4885FAAH 217/4885SMN1; SMN2 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.